Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4453309
Max Phase: Preclinical
Molecular Formula: C64H126N12O11S
Molecular Weight: 1271.85
Molecule Type: Unknown
Associated Items:
ID: ALA4453309
Max Phase: Preclinical
Molecular Formula: C64H126N12O11S
Molecular Weight: 1271.85
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCCCCCCCCCCCCCCCOC(=O)NCCSC[C@H](NC(=O)NCCCCCCCCCCCCCC)C(=O)N[C@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O
Standard InChI: InChI=1S/C64H126N12O11S/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-36-47-87-64(86)70-46-48-88-50-56(76-63(85)69-45-35-25-23-21-19-16-14-12-10-8-6-4-2)61(82)75-55(49-77)60(81)73-52(38-28-32-42-66)58(79)71-51(37-27-31-41-65)57(78)72-53(39-29-33-43-67)59(80)74-54(62(83)84)40-30-34-44-68/h51-56,77H,3-50,65-68H2,1-2H3,(H,70,86)(H,71,79)(H,72,78)(H,73,81)(H,74,80)(H,75,82)(H,83,84)(H2,69,76,85)/t51-,52-,53-,54-,55+,56-/m0/s1
Standard InChI Key: ZGVJKYKTGQXRAH-XQLYAWKKSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1271.85 | Molecular Weight (Monoisotopic): 1270.9390 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Du X, Qian J, Wang Y, Zhang M, Chu Y, Li Y.. (2019) Identification and immunological evaluation of novel TLR2 agonists through structure optimization of Pam3CSK4., 27 (13): [PMID:31101493] [10.1016/j.bmc.2019.05.005] |
Source(1):